Rigel Pharma Closes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) said that it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromboycytopenic purpura or ITP. The first study in this program completed enrollment at the end of January and the second study has now completed enrollment.The results from the first study are expected in the middle of 2016, with the results for the second study expected shortly thereafter.

Earlier this year Rigel initiated a Phase 2 clinical trial in a second autoimmune disorder of the blood, autoimmune hemolytic anemia or AIHA. The purpose of this clinical trial is to evaluate the safety and efficacy of fostamatinib in patients with chronic AIHA. This disorder affects an estimated 40,000 Americans, for whom no approved treatment options currently exist.